No Data
Bide Pharmatech Co., Ltd.'s (SHSE:688073) Stock Has Seen Strong Momentum: Does That Call For Deeper Study Of Its Financial Prospects?
Bide Pharmaceuticals: third quarter report 2024
Third Quarter Report 2024
Bede Pharmaceuticals (688073.SH) released its performance for the first three quarters, with a net income of 83.85 million yuan, a year-on-year decrease of 26.05%.
Bide Pharmaceutical (688073.SH) disclosed its third quarter report for 2024. During the reporting period, the company achieved revenue of 8.1...
BiDe Pharmaceutical (688073.SH): The net income in the first three quarters was 83.8539 million yuan, a year-on-year decrease of 26.05%.
GElonghui Oct. 23 - Bide Pharmaceuticals (688073.SH) announced that the company's revenue in the first three quarters was 0.811 billion yuan, a year-on-year increase of 0.79%; net income attributable to shareholders of the listed company was 83.8539 million yuan, a year-on-year decrease of 26.05%; net income attributable to shareholders of the listed company excluding non-recurring gains and losses was 72.3904 million yuan, a year-on-year decrease of 40.18%; basic earnings per share were 0.94 yuan.
Intensifying competition in the domestic CRO market is eroding profits, BiDe Pharmaceutical claims it will strengthen its overseas market | Direct hit earnings conference
①Due to factors such as the slowdown in investment and financing for innovative drugs, increased competition among CRO companies, BeiDe Medicine's domestic revenue continues to decline, dragging down overall performance and leading to a sharp decrease in net income; ②In contrast, overseas market revenue remains growth, BeiDe Medicine's director, Dai Lan, revealed that there will be corresponding increase in overseas market BD personnel to carry out promotional work in the future.
Are Bide Pharmatech Co., Ltd.'s (SHSE:688073) Fundamentals Good Enough to Warrant Buying Given The Stock's Recent Weakness?No Data
No Data
